# Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

> **NCT02045836** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 865 (actual)

## Conditions studied

- Herpes Zoster
- Herpes Zoster Vaccine

## Interventions

- **BIOLOGICAL:** Herpes Zoster vaccine GSK 1437173A
- **BIOLOGICAL:** Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™

## Key facts

- **NCT ID:** NCT02045836
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-05
- **Primary completion:** 2015-07-02
- **Final completion:** 2016-06-17
- **Target enrollment:** 865 (ACTUAL)
- **Last updated:** 2021-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045836, "Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02045836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*